Novavax (NASDAQ:NVAX) : 6 Wall Street analysts covering Novavax (NASDAQ:NVAX) believe that the average level the stock could reach for the short term is $13.15. The maximum price target given is $17 and the minimum target for short term is around $6, hence the standard deviation is calculated at $3.81.
Other Equity analysts have also commented on the company shares. Chardan Capital initiates coverage on Novavax (NASDAQ:NVAX). Chardan Capital has a Neutral rating on the shares. As per the latest report, the brokerage house announces the price target to $5.75 per share. The rating by the firm was issued on April 4, 2016.
Novavax (NASDAQ:NVAX): stock turned positive on Thursday. Though the stock opened at $6.77, the bulls momentum made the stock top out at $6.91 level for the day. The stock recorded a low of $6.695 and closed the trading day at $6.91, in the green by 3.29%. The total traded volume for the day was 3,048,117. The stock had closed at $6.69 in the previous days trading.
The company shares have dropped -39.84% from its 1 Year high price. On Aug 11, 2015, the shares registered one year high at $15.01 and the one year low was seen on Feb 3, 2016. The 50-Day Moving Average price is $5.73 and the 200 Day Moving Average price is recorded at $5.85. On the companys insider trading activities, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Novavax Inc, Evans Gary C had sold 18,998 shares worth of $123,487 in a transaction dated June 6, 2016. In this transaction, 18,998 shares were sold at $6.5 per share.
Novavax, Inc. (Novavax) is a clinical-stage vaccine company engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. The Companys product pipeline focuses on a variety of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Companys lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. The Company is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. The Company is developing additional pre-clinical stage programs in a variety of infectious diseases, including Middle East respiratory syndrome (MERS).